Interpretation of Clinical Practice Guidelines for Management of Kidney Injury during Anticancer Drug Therapy 2022 (I): clinical questions and good practice statements
10.3760/cma.j.cn114015-20240319-00178
- VernacularTitle:《抗肿瘤药物治疗期间肾损伤管理临床实践指南（2022）》解读（一）：临床问题与良好实践声明
- Author:
Xizi ZHENG
1
;
Lingyi XU
1
;
Qingqing ZHOU
1
;
Li YANG
1
Author Information
1. 北京大学第一医院肾内科，北京大学肾脏病研究所，卫生部肾脏疾病重点实验室，慢性肾脏病防治教育部重点实验室（北京大学），中国医学科学院免疫介导肾病诊治创新单元，北京 100034
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
Acute kidney injury;
Renal insufficiency;
Guideline;
Interpretation
- From:
Adverse Drug Reactions Journal
2024;26(5):261-267
- CountryChina
- Language:Chinese
-
Abstract:
Kidney disease management is a great concern that needs to be addressed urgently in cancer patients during their disease course and treatment process. To help medical professionals involved in cancer pharmacotherapy cope with various kidney issues during the whole management course of cancer patients, the Japanese Society of Nephrology, Japan Society of Clinical Oncology, Japanese Society of Medical Oncology, and Japanese Society of Nephrology and Pharmacotherapy have formulated the Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022. These guidelines cover renal function assessment, management of drug-induced nephrotoxicity, anticancer drug regimen planning, and chronic kidney disease treatment in cancer survivors and include 11 clinical questions and 4 good practice statements. In addition, these guidelines also comprise 16 general reviews that explain background questions. This article interprets the clinical questions and good practice statements, aiming to facilitate the understanding of these guidelines which may do some help in improving clinical practice.
